Le Lézard
Classified in: Health
Subject: SVY

Global Basal Cell Carcinoma Treatment Market: Leading Players to Involve in Partnerships With Local Participants, Says TMR


ALBANY, New York, February 15, 2018 /PRNewswire/ --

According to the estimation of TMR, the global basal cell carcinoma treatment market was worth US$4.66 bn in 2016. The opportunity in this market is projected to expand at a CAGR of 9.20% during the period from 2017 to 2025 and reach US$10.14 bn by the end of the period of the forecast. Among all the treatment types, the demand for surgeries is higher, thanks to their efficiency. Analysts predict this trend to remain so over the next few years, establishing the dominance of the surgical basal cell carcinoma treatment segment. Among end users, basal cell carcinoma treatments find most significant usage in hospitals and specialty clinics. Geographically, North America is projected to continue on the top in the near future, thanks to the presence of an advanced medical and healthcare infrastructure and the rising expenditure on healthcare in this region, states the market report.

Rising Prevalence of Cutaneous Malignancies to Boost Demand 

"The market for basal cell carcinoma treatment is benefiting significantly from the increasing prevalence of basal cell carcinoma, rising consciousness among consumers about the disease, and the presence of favorable reimbursement scenario in high prevalence regions," says a TMR analyst. The rising prevalence of various cutaneous malignancies, specifically non-melanoma skin cancer, such as basal cell carcinoma and squamous cell carcinoma, is influencing the demand for basal cell carcinoma treatment tremendously across the world.

Get PDF Brochure for Research Insights at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40139

The increase in geriatric population, who are highly susceptible to several types of skin diseases, such as actinic keratosis and various other non-melanoma skin malignancies, is also boosting the growth of the global basal cell carcinoma treatment market, reports the research study.

Higher Propensity of Basal Cell Carcinoma to Remain Underdiagnosed to Obstruct Market's Growth 

On the other hand, the high propensity of basal cell carcinoma remaining underdiagnosed may obstruct the growth trajectory of the worldwide market for basal cell carcinoma treatment over the next few years. The high treatment cost and the lack of awareness in emerging economies can also restrain the market's growth in the years to come. However, the rising demand for better disease treatments in emerging economies, as a result of escalating disposable income, is expected to provide lucrative growth opportunities for market players in the near future, states the report.

Request a Custom Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=40139

The rivalry between Sun Pharmaceuticals Ltd., Valeant Pharmaceuticals International Inc., Mylan N.V., F. Hoffmann-La Roche Ltd., and Merck & Co. Inc. characterizes the competitive landscape present in the global basal cell carcinoma treatment market, states a new research study by Transparency Market Research (TMR). Currently, the leading players are focusing on increasing the efficiency of their products by inculcating the latest technologies, in order to gain a competitive edge over the peers. Over the coming years, these participants are expected to involve more in partnerships with regional players in a bid to strengthen their regional presence, notes the research study.

Purchase your own copy of Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=40139&ltype=S      

The review is based on a report by Transparency Market Research (TMR), titled "Basal Cell Carcinoma Treatment Market (Treatment type - Surgical (Surgical Excision, Electrodessication & Cutterage, Moh's Surgery, and Cryosurgery), Drugs (Topical Treatment, Advanced Medication, and Other), and Others (Radiation Therapy, Photodynamic Therapy, and Laser Therapy); End-users- Hospitals, Specialty Clinics, and Others: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017-2025."

Key Takeaways 


The global basal cell carcinoma treatment market has been segmented as follows:

By Treatment Type 


By End User 


By Geography 


Popular Research Reports by TMR: 


https://www.transparencymarketresearch.com/global-blood-cell-analyzer-market.html


https://www.transparencymarketresearch.com/cell-based-assays.html

About Us 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]

Website: http://www.transparencymarketresearch.com

Research Blog: https://theglobalhealthnews.com/


These press releases may also interest you

at 22:03
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: